Description
In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy pro…
Amendment chain · 5 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $5,412,045 at start, $2,655,429 after amendment #5 (−$2,756,616).
- #12020-12-17$5,412,045
- #22021-03-04$5,887,037+$474,992
- #32021-10-13$5,887,037
- #42022-03-29$3,791,179-$2,095,858
- #52023-02-27$2,655,429-$1,135,750
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-12-17 | $5,412,045 | — | In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-… |
| #2 amendment | 2021-03-04 | $5,887,037 | +$474,992 | In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-… |
| #3 amendment | 2021-10-13 | $5,887,037 | +$0 | In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-… |
| #4 amendment | 2022-03-29 | $3,791,179 | −$2,095,858 | In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-… |
| #5 amendment | 2023-02-27 | $2,655,429 | −$1,135,750 | In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-… |
Related records · 10
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 864736772)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 172-2020-2021-Q2-957299 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $25,000 | FY2021 |
| 276-2020-2021-Q2-00422 | Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique · REGI - Business Scale-up and Productivity | $1,000,000 | FY2021 |
| 276-2020-2021-Q2-00735 | Atlantic Canada Opportunities Agency | Agence de promotion économique du Canada atlantique · REGI - Business Scale-up and Productivity | $900,000 | FY2021 |
| 172-2020-2021-Q1-948901 | National Research Council Canada | Conseil national de recherches Canada · Industrial Research Assistance Program – Contributions to Firms | $636,596 | FY2021 |
| 172-2020-2021-Q1-951167 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $640,332 | FY2021 |
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q3-957553 · retrieved 2026-11-15.